A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 45
• 9 sites in 2 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced non-small cell lung cancer that has a KRAS G12C mutation. It tests the safety and effect of the drug BBO-8520.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Advanced non-small cell lung cancer.

Biomarker or test result

The cancer must have a KRAS G12C mutation.

Read by machine on 9 Nov 2026.

Sites (9)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details